about
Effect of doxazosin GITS on blood pressure in hypertensive and normotensive patients: a review of hypertension and BPH studies.Consequences of the increased autonomic nervous drive in hypertension, heart failure and diabetes.The sympathetic nervous system and the kidney: its importance in renal diseases.Therapy of hypertension and metabolic syndrome: today's standard and tomorrow's perspectives.Moxonidine: pharmacology, clinical pharmacology and clinical profile.Insulin resistance and diabetes in the context of treatment of hypertension.Sympathetic control of circulation in hypertension and congestive heart failure.The comparative pharmacology of angiotensin II receptor antagonists.An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension.The renin-angiotensin system and cardiovascular disease.Angiotensin II type 1 receptor blockade: a novel therapeutic concept.Differences among angiotensin II type 1 receptor blockers: characteristics of candesartan cilexetil.Improving antihypertensive efficacy while maintaining placebo-like tolerability.Achieving quality 24-h blood pressure control with candesartan cilexetil.Efficacy and tolerability of candesartan cilexetil in special patient groups.Improving prognosis in hypertension: exploring the benefits of angiotensin II type 1 receptor blockade.Preserving target-organ function with candesartan cilexetil in patients with hypertension.Exploring new treatment strategies in heart failure.Inhibiting renin-angiotensin in the brain: the possible therapeutic implications.Renal effects of angiotensin II receptor antagonists.The role of angiotensin II receptor antagonists in the management of diabetes.Ambulatory blood pressure monitoring to assess the comparative efficacy and duration of action of a novel new angiotensin II receptor blocker--telmisartan.Pharmacological differences among angiotensin II receptor antagonists.Clinical differences among angiotensin II receptor antagonists.Hypertension and diabetes: the scope of the problem.Achieving blood pressure targets in the management of hypertension.Clinical comparative trials of angiotensin II type 1 (AT1)-receptor blockers.AT1-receptor blocker-based combination therapy in hypertension.Importance of smooth and sustained blood pressure control in preventing cardiovascular morbidity and mortality.The relationship between dose and antihypertensive effect for different AT1-receptor blockers.Pharmacology of AT1-receptor blockers.Results of the STOP-Hypertension-2 trial.Clevidipine for severe hypertension in patients with renal dysfunction: a VELOCITY trial analysisAntihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension.Pharmacological profile of barnidipine: a single optical isomer dihydropyridine calcium antagonist.Efficacy and tolerability of once-daily barnidipine in the clinical management of patients with mild to moderate essential hypertension.Diversity and intensity of adverse events in the treatment of hypertension with barnidipine.Hemodynamic profiles of antihypertensive agents.Syndrome X.Male fat distribution and cardiovascular risk.
P1433
Q33149023-EE888BF8-DF3D-4A25-ACC3-EFD3C8887967Q33631952-69154952-2E2A-4F50-8658-D14BA2E43A7FQ33631957-2CDF65A8-7B07-4E45-84A5-E8796F7BEE99Q33631961-7B220903-F009-4147-BF37-292014860E28Q33631966-EB62C03F-F2DD-4F83-821A-549A98933900Q33631971-EE077209-786E-4277-9077-3F295E3B08CDQ33631975-270673F9-9431-460D-B0B4-83BD88E6FAEAQ33845271-77DC1145-D8A4-4F8F-B606-47B0E0C70210Q34008454-CE327A28-104C-4968-A269-C18A11E2874BQ34074055-845F8054-7D7F-4FDD-811C-420ED2FA388AQ34074059-08FF683B-5471-4CBA-9D55-128210416CF3Q34074064-54113AD5-552F-4DD6-A68B-6DE591ED331EQ34074067-7A785CD9-0DDC-4B2A-92D3-7A06FBB624E1Q34074072-01E436A6-4D8D-4DDA-8F66-517A97F5939FQ34074076-426E8507-1195-4301-BCF5-9B812D03745BQ34074080-70C73649-5E7B-4D0B-9A6A-0CA3912BCC78Q34074085-7723BA71-0C10-4F93-AC3F-63D9603532D4Q34074090-FAFEB517-7AB6-42E9-8E04-A5720BB608C6Q34238814-5138B7AA-07C0-48CF-9322-3F5EF0012747Q34238820-A5C31404-8D02-436C-84D5-959292D3B0CFQ34238826-2DFBF338-54AD-4CEE-B001-C11B13DDA09DQ34238834-7AE3C8CE-40B4-4A99-80F9-FD761E660CF8Q34315114-F280A413-8086-4DA4-8877-6BD078352801Q34315120-709C97F5-94D4-4C6A-BEE6-D981100F1C22Q34315126-9A098C70-30E6-4656-9788-2139C918FD73Q34315132-2AEE3EAD-F0F2-470B-94B7-41211F0AE73FQ34421212-22AEE6B5-9ADC-4D07-ADA0-DF3B745A3C90Q34421218-1A2C436C-151C-4CD4-9C1F-067CDDCDEEFFQ34421223-C919D655-850B-4F28-B9C3-425AF74A01D4Q34421228-7138CF18-DD10-4E16-9AB4-30856F4FF672Q34421234-A9EA01CE-F430-4AE4-B0B4-A378A36DB7B3Q34511649-41D6501D-F627-4CFC-88FC-931268B51BA2Q34572190-5F4DE38D-9DAF-492B-A70A-5968D1B21561Q34719691-D88C1BC2-BF6A-4300-9364-1AA6CC49709CQ34749152-E1477812-9EE8-4C49-979E-38A7ADF091DFQ34749157-7D64AD2B-A599-4C64-9504-128D44819FDEQ34749164-72790AD8-EDAE-45AC-B76E-49D059DBE133Q35245173-F7BCFEC9-1670-44F3-BB11-F4ED8C286A3BQ35248725-9F45B623-CD56-4475-9121-9CCB7900E4DAQ35248734-56925D30-5712-464F-B33D-0DD667E97154
P1433
description
journal
@en
revista científica
@es
rivista scientifica
@it
vědecký časopis
@cs
wetenschappelijk tijdschrift van Taylor & Francis
@nl
wissenschaftliche Fachzeitschrift
@de
مجلة
@ar
name
Blood Pressure. Supplement
@ast
Blood Pressure. Supplement
@en
Blood Pressure. Supplement
@es
Blood Pressure. Supplement
@it
Blood Pressure. Supplement
@nl
type
label
Blood Pressure. Supplement
@ast
Blood Pressure. Supplement
@en
Blood Pressure. Supplement
@es
Blood Pressure. Supplement
@it
Blood Pressure. Supplement
@nl
prefLabel
Blood Pressure. Supplement
@ast
Blood Pressure. Supplement
@en
Blood Pressure. Supplement
@es
Blood Pressure. Supplement
@it
Blood Pressure. Supplement
@nl
P1055
P1058
P1156
P123
P1476
Blood Pressure. Supplement
@en